PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
58 hedge funds and large institutions have $53M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 3 closing their positions.
23,800% more call options, than puts
Call options by funds: $239K | Put options by funds: $1K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
16% more funds holding
Funds holding: 50 → 58 (+8)
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $60M → $53M (-$7.02M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$396K |
| 2 |
Renaissance Technologies
New York
|
+$299K |
| 3 |
William Blair & Company
Chicago,
Illinois
|
+$242K |
| 4 |
BlackRock
New York
|
+$210K |
| 5 |
PTP
Platform Technology Partners
New York
|
+$172K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.31M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$175K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$89.5K |
| 4 |
State Street
Boston,
Massachusetts
|
-$81.6K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$51.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIP
51
Ameritas Investment Partners
Lincoln,
Nebraska
| $4K | – | – | – |
|
52
UBS Group
Zurich,
Switzerland
| $4K | +$4.68K | +1,308 | New |
|
|
CG
53
Cutler Group
San Francisco,
California
| $3K | +$2.15K | +600 | +150% |
|
|
PAM
54
Panagora Asset Management
Boston,
Massachusetts
| $2K | – | – | – |
|
|
KTC
55
Kistler-Tiffany Companies
Berwyn,
Pennsylvania
| $1K | – | – | – |
|
|
AIG
56
American International Group
New York
| $30 | -$913 | -255 | -3% |
|
|
57
Dimensional Fund Advisors
Austin,
Texas
| – | -$175K | -49,748 | Closed |
|
|
WS
58
Wedbush Securities
Los Angeles,
California
| – | -$49K | -13,865 | Closed |
|
|
GWM
59
Geneos Wealth Management
Englewood,
Colorado
| – | -$3K | -1,000 | Closed |
|
|
AWM
60
Accel Wealth Management
Waverly,
Iowa
| – | +$358 | +100 | New |
|
PHAS Hedge Fund Activity: Q4 2020 in Review
58 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q4 2020, worth a combined $53M — down 12% from $60M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new PHAS positions and 3 closed out — a net gain of 8 holders — while 17 added to existing stakes and 16 trimmed.
The largest buyer was Parkman Healthcare Partners, opening a new position worth an estimated $396K. The largest seller was Wellington Management Group, cutting an estimated $6.31M.
- 58 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q4 2020, up from 50 in Q3 2020.
- Funds reported $53M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q4 2020, down 12% quarter-over-quarter.
- 11 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q4 2020 and 3 closed out, a net change of +8 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q4 2020 was Parkman Healthcare Partners, an estimated $396K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q4 2020 was Wellington Management Group, an estimated $6.31M sold.
Based on aggregated 13F filings for Q4 2020.